Sanofi, Translate Bio Initiate Early-Stage mRNA Influenza Vaccine Trial

Sanofi Pasteur, vaccine unit of Sanofi SA SNY and Translate Bio Inc TBIO have initiated a Phase 1 trial evaluating an mRNA-based investigational vaccine against seasonal influenza.
The 280-subject trial will assess the safety and immunogenicity (immune response) of the monovalent (single-strain) mRNA-based flu vaccine candidate.
The trial will evaluate several dose levels of both vaccine formulations given to healthy adults 18 - 49 years of age.
Interim data from the trial is expected by the end of 2021.
Sanofi and Translate Bio have developed and will evaluate two formulations of the vaccine (MRT5400 and MRT5401) in the Phase 1 influenza mRNA vaccine clinical trial.
The two formulations differ in the lipid nanoparticle that contains the mRNA.
Preclinical results were shared previously at the annual mRNA Healthcare Conference in November 2020.
Under the collaboration, in March, the companies initiated a Phase 1/2 trial of their mRNA COVID-19 vaccine candidate.
Earlier, Translate Bio also received a $50 million manufacturing milestone under the collaboration related to its influenza mRNA vaccine program.
Price Action: TBIO shares closed at $18.74 on Monday.